Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RKI983 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| RKI983 | DRUG | - |
Inclusion Criteria: * Males and females, ≥18 years of age, with primary open angle glaucoma and ocular hypertension * Females must be post-menopausal or surgically sterile Exclusion Criteria: * Other types of glaucoma * Eye pressure lowering surgeries * A history of or current eye conditions or m...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
RKI983 is an investigational small molecule being developed for the treatment of glaucoma. It is formulated as eye drops and has been studied in patients with primary open angle glaucoma and ocular hypertension. The drug is currently in Phase 1 clinical development.
RKI983 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is in Phase 1 clinical development for the treatment of glaucoma.
RKI983 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial evaluating the drug has been completed, with no active trials currently ongoing.
RKI983 has been studied in one clinical trial, identified as NCT00515424. This Phase 1 study, titled "Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension," was completed in the United States with 90 participants.
RKI983 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial has been completed, but the drug has not yet received regulatory approval for the treatment of glaucoma.